Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 578

Results For "RI"

11113 News Found

Morepen Board proposed dividend after 23 years
News | May 13, 2025

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25


Kwality Pharmaceuticals concludes regulatory audit for Zimbabwe
News | May 12, 2025

Kwality Pharmaceuticals concludes regulatory audit for Zimbabwe

This marks yet another milestone in our series of successful audits over the past year


Zydus receives final approval from USFDA for Glatiramer Acetate Injection
Drug Approval | May 12, 2025

Zydus receives final approval from USFDA for Glatiramer Acetate Injection

Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes


Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr
News | May 12, 2025

Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr

The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025


Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
News | May 12, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr

The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025


Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
News | May 12, 2025

Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr

The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025


Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
News | May 12, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr

The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025


Agilent inaugurates India Solution Center to accelerate innovation
News | May 09, 2025

Agilent inaugurates India Solution Center to accelerate innovation

Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets


Lupin launches Eslicarbazepine Acetate tablets in US
Drug Approval | May 08, 2025

Lupin launches Eslicarbazepine Acetate tablets in US

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity


Suven Pharmaceuticals is now Cohance Lifesciences
News | May 08, 2025

Suven Pharmaceuticals is now Cohance Lifesciences

The change of name has been carried on pursuant to the Scheme of Amalgamation